PapersPMID:40759997
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT
- Dose studied, every finding
- Oral Puritan's Pride Turmeric Curcumin 500 mg capsules (Curcuma longa root 450 mg plus turmeric extract 50 mg standardised to 95% curcuminoids), one capsule three times daily after meals (1500 mg/day) for 14 weeks, added to conventional therapy
- Population, every finding
- Adults aged 50-74 y with type 2 diabetes and a 10-year ASCVD risk score >=5%, Cairo, Egypt; 85 randomised (42 curcumin, 43 control), 72 analysed (36 per group); open-label trial in which the control arm received conventional therapy only, with no placebo; the paper declares no primary endpoint and powered its sample size on change in HDL-C; LDL-C calculated by the Friedewald equation, HDL-C by enzymatic colorimetric assay
What moved
How to read these marks →“Furthermore, at the end of the study, the Curcumin group reported lower LDL levels ( P = 0.024) and higher HDL levels ( P = 0.024) versus the control group.”
- Decreases LDL cholesterol
moderate
- Increases HDL cholesterol
moderatereplicated ×2
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Seventy-two diabetic patients (T2DM) with an ASCVD risk score of ≥ 5%; curcumin 500 mg Turmeric curcumin® thrice daily plus conventional therapy
- Participants
- 72
- Comparator
- no treatment
- Duration
- not reported
- Endpoints measured
- 8
- Declined
- another reason, stated per paper
curcumin